Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Apr 9, 2010

Premium

Pietro Scalfaro has joined the board of diagnostics technology development firm Biocartis, the company said this week.

Scalfaro is chief project officer at the Debiopharm Group, which develops biologics and small-molecule drugs.

Debiopharm was one of two new investors in Biocartis in a Series B financing round announced this week that raised €30 million ($40 million). Johnson & Johnson Development was the other new investor. The firm will use the proceeds to further build out the first version of its proprietary platform, the company said in a statement.

Biocartis, founded in 2007 and based in Lausanne, Switzerland, has licensed and developed new technologies to build a "broadly applicable new diagnostics platform for low to highly multiplexed detection, quantification, and amplification of molecular-based biomarkers, including nucleic acids, proteins, and small molecules," the company said in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.